Global Rare Disease Drug

Rare Disease Drug Comprehensive Study by Type (Biologics, Non-Biologics), Application (Hospitals, Clinics, Others), Disease (Oncologic Diseases, Metabolic Diseases, Hematologic & Immunologic Diseases, Infectious Diseases, Neurologic Diseases, Other Rare Diseases), Form (Tablet, Powder, Injections, Others), Distribution Channel (Pharmacies, Grocery Stores, Internet Sales, Mail Order, Direct Marketing Routes, Other Convenience Stores), Indication (Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Cystic Fibrosis, Glioma, Pancreatic Cancer, Ovarian Cancer, Multiple Myeloma, Duchenne Muscular Dystrophy, Graft vs Host Disease, Renal Cell Carcinoma, Others) Players and Region - Global Market Outlook to 2030

Rare Disease Drug Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Rare Disease Drug Market Scope
The rare diseases drug highly conditions as an orphan drug. It is highly utilized in the United States regions. There are near about 7000 rare diseases across the globe. The highest number of patients related to the rare disease drugs in the United States, the European Union, and Japan. The market is growing at a higher rate because of the increased number of current willingness and the increasing number of industry players. With the growing concern towards rare disease drugs, many emerging economies are focusing on development initiatives. For instance, India is looking to set rare diseases drug policy and also developing domestic treatments. In India increasing the occurrence of Duchenne muscular dystrophy among children forced the Ministry of Health and Family Welfare forming the national Policy for the treatment of rare diseases. Globally, also various legislations are developing in concern of the rare disease drugs such as the United States Orphan Drug Act is initiating various rare disease drug development.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
Key Companies ProfiledNovartis (Switzerland), Bristol-Myers Squibb Company (United States), Celgene Corporation (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Pfizer, Inc. (United States), Sanofi S.A. (France), Alexion Pharmaceuticals, Inc. (United States), Eli Lilly and Company (United States), Novo Nordisk A/S (Denmark), AstraZeneca (United Kingdom), Eisai Co., Ltd. (Japan) and Daiichi Sankyo Company Limited (Japan)
CAGR%


The global rare disease drug market is highly competitive and consists of some key players. In terms of market share, few of the key players presently dominate the global market. These market players are leveraging on strategic collaborative creativities to intensification their market share and escalation their profitability. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Rare Disease Drug market throughout the predicted period.

Novartis (Switzerland), Bristol-Myers Squibb Company (United States), Celgene Corporation (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Pfizer, Inc. (United States), Sanofi S.A. (France), Alexion Pharmaceuticals, Inc. (United States), Eli Lilly and Company (United States), Novo Nordisk A/S (Denmark), AstraZeneca (United Kingdom), Eisai Co., Ltd. (Japan) and Daiichi Sankyo Company Limited (Japan) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Bayer AG (Germany), GlaxoSmithKline (United Kingdom), Merck & Co., Inc. (United States), Johnson & Johnson (United States) and Biogen, Inc. (United States).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global Rare Disease Drug market by Type , by Application (Hospitals, Clinics and Others) and Region with country level break-up. On the basis of Type, Pharmacies are dominating the market in the year 2023

On the basis of application, Hospitals segment is dominating the market in the year 2023

On the basis of geography, the market of Rare Disease Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2023.

Market Leaders and their expansionary development strategies
In February 2019, Ipsen announced the acquisition of the Clementia Pharmaceuticals for the treatment of the key late-stage clinical asset palovarotene, multiple osteochondromas, and others. Through this agreement, the company is aiming to enhance its product portfolio in rare diseases across the globe.
In August 2019, Critical path Institute and advocacy organization national organization revealed its new data and analytics platform for rare disorders. This platform is having multiple sources including clinical trials, observational studies, real-time data, and others.
The rare disease drugs are regulated by the FDA. Recently, in the market there are three new drugs approved by the FDA for the treatment of two new types of rare diseases including non-Hodgkin lymphomas, and Fabry disease. The new drugs are Mogamulizumab-kpkc injection, Lanadelumab-flyo, and migalastat. Recently, the United States regulators registered COVID-19 as rare disease treatment. For this FDA grant an experimental medicine known as remdeivir for the treatment of coronavirus disease. With the continuously rising COVID-19 cases in the United States region, the health agency's made decisions to provide remdesivir at a lower price (if it will be approved).

Influencing Trend:
Increase in investment from the manufacturers of the leading drug across the globe to developing therapies, invest more in research and focused on offering innovative solutions. Which can bring high potential to offer a solution which impacted on rare diseases. The company is providing drugs to provide patients which includes emerging markets, with advance healthcare.

Market Growth Drivers:
Rising Awareness among Consumers, Technology Advancement in Manufacturing Process and Increasing Number of Rare Diseases in North America Regions, it almost occurs in one in ten American

Challenges:
The high challenge for patients, they are facing huge diversity in their clinical histories. These variables include age, disease progression, and various outcomes, whether they are clinician-reported, observer-reported, or patient-reported outcomes.

Restraints:
Fluctuation in Cost of Raw Materials Associated With Rare Disease Drugs and There are around 95 percent of rare disease which do not have any treatment across the globe

Opportunities:
Development in Drug Manufacturing Countries and Rising Investment of Research and Development on the Rare Disease Drugs, in Terms of Inventing New Treatments

Key Target Audience
Venture Capitalists and Private Equity Firms, New Entrants/Investors, Analysts and Strategic Business Planners, Rare Disease Drug Manufacturers, Suppliers and Distributors, Raw Material Suppliers, Government Regulatory and Research Organizations and End-Use Industries

Report Objectives / Segmentation Covered

By Application
  • Hospitals
  • Clinics
  • Others
By Disease
  • Oncologic Diseases
  • Metabolic Diseases
  • Hematologic & Immunologic Diseases
  • Infectious Diseases
  • Neurologic Diseases
  • Other Rare Diseases

By Form
  • Tablet
  • Powder
  • Injections
  • Others

By Distribution Channel
  • Pharmacies
  • Grocery Stores
  • Internet Sales
  • Mail Order
  • Direct Marketing Routes
  • Other Convenience Stores

By Indication
  • Non-Hodgkin Lymphoma
  • Acute Myeloid Leukemia
  • Cystic Fibrosis
  • Glioma
  • Pancreatic Cancer
  • Ovarian Cancer
  • Multiple Myeloma
  • Duchenne Muscular Dystrophy
  • Graft vs Host Disease
  • Renal Cell Carcinoma
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Awareness among Consumers
      • 3.2.2. Technology Advancement in Manufacturing Process
      • 3.2.3. Increasing Number of Rare Diseases in North America Regions, it almost occurs in one in ten American
    • 3.3. Market Challenges
      • 3.3.1. The high challenge for patients, they are facing huge diversity in their clinical histories. These variables include age, disease progression, and various outcomes, whether they are clinician-reported, observer-reported, or patient-reported outcomes.
    • 3.4. Market Trends
      • 3.4.1. Increase in investment from the manufacturers of the leading drug across the globe to developing therapies, invest more in research and focused on offering innovative solutions. Which can bring high potential to offer a solution which impacted on rare diseases. The company is providing drugs to provide patients which includes emerging markets, with advance healthcare.
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Rare Disease Drug, by Application, Disease, Form, Distribution Channel, Indication and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Rare Disease Drug (Value)
      • 5.2.1. Global Rare Disease Drug by: Application (Value)
        • 5.2.1.1. Hospitals
        • 5.2.1.2. Clinics
        • 5.2.1.3. Others
      • 5.2.2. Global Rare Disease Drug by: Disease (Value)
        • 5.2.2.1. Oncologic Diseases
        • 5.2.2.2. Metabolic Diseases
        • 5.2.2.3. Hematologic & Immunologic Diseases
        • 5.2.2.4. Infectious Diseases
        • 5.2.2.5. Neurologic Diseases
        • 5.2.2.6. Other Rare Diseases
      • 5.2.3. Global Rare Disease Drug by: Form (Value)
        • 5.2.3.1. Tablet
        • 5.2.3.2. Powder
        • 5.2.3.3. Injections
        • 5.2.3.4. Others
      • 5.2.4. Global Rare Disease Drug by: Distribution Channel (Value)
        • 5.2.4.1. Pharmacies
        • 5.2.4.2. Grocery Stores
        • 5.2.4.3. Internet Sales
        • 5.2.4.4. Mail Order
        • 5.2.4.5. Direct Marketing Routes
        • 5.2.4.6. Other Convenience Stores
      • 5.2.5. Global Rare Disease Drug by: Indication (Value)
        • 5.2.5.1. Non-Hodgkin Lymphoma
        • 5.2.5.2. Acute Myeloid Leukemia
        • 5.2.5.3. Cystic Fibrosis
        • 5.2.5.4. Glioma
        • 5.2.5.5. Pancreatic Cancer
        • 5.2.5.6. Ovarian Cancer
        • 5.2.5.7. Multiple Myeloma
        • 5.2.5.8. Duchenne Muscular Dystrophy
        • 5.2.5.9. Graft vs Host Disease
        • 5.2.5.10. Renal Cell Carcinoma
        • 5.2.5.11. Others
      • 5.2.6. Global Rare Disease Drug Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Rare Disease Drug (Volume)
      • 5.3.1. Global Rare Disease Drug by: Application (Volume)
        • 5.3.1.1. Hospitals
        • 5.3.1.2. Clinics
        • 5.3.1.3. Others
      • 5.3.2. Global Rare Disease Drug by: Disease (Volume)
        • 5.3.2.1. Oncologic Diseases
        • 5.3.2.2. Metabolic Diseases
        • 5.3.2.3. Hematologic & Immunologic Diseases
        • 5.3.2.4. Infectious Diseases
        • 5.3.2.5. Neurologic Diseases
        • 5.3.2.6. Other Rare Diseases
      • 5.3.3. Global Rare Disease Drug by: Form (Volume)
        • 5.3.3.1. Tablet
        • 5.3.3.2. Powder
        • 5.3.3.3. Injections
        • 5.3.3.4. Others
      • 5.3.4. Global Rare Disease Drug by: Distribution Channel (Volume)
        • 5.3.4.1. Pharmacies
        • 5.3.4.2. Grocery Stores
        • 5.3.4.3. Internet Sales
        • 5.3.4.4. Mail Order
        • 5.3.4.5. Direct Marketing Routes
        • 5.3.4.6. Other Convenience Stores
      • 5.3.5. Global Rare Disease Drug by: Indication (Volume)
        • 5.3.5.1. Non-Hodgkin Lymphoma
        • 5.3.5.2. Acute Myeloid Leukemia
        • 5.3.5.3. Cystic Fibrosis
        • 5.3.5.4. Glioma
        • 5.3.5.5. Pancreatic Cancer
        • 5.3.5.6. Ovarian Cancer
        • 5.3.5.7. Multiple Myeloma
        • 5.3.5.8. Duchenne Muscular Dystrophy
        • 5.3.5.9. Graft vs Host Disease
        • 5.3.5.10. Renal Cell Carcinoma
        • 5.3.5.11. Others
      • 5.3.6. Global Rare Disease Drug Region
        • 5.3.6.1. South America
          • 5.3.6.1.1. Brazil
          • 5.3.6.1.2. Argentina
          • 5.3.6.1.3. Rest of South America
        • 5.3.6.2. Asia Pacific
          • 5.3.6.2.1. China
          • 5.3.6.2.2. Japan
          • 5.3.6.2.3. India
          • 5.3.6.2.4. South Korea
          • 5.3.6.2.5. Taiwan
          • 5.3.6.2.6. Australia
          • 5.3.6.2.7. Rest of Asia-Pacific
        • 5.3.6.3. Europe
          • 5.3.6.3.1. Germany
          • 5.3.6.3.2. France
          • 5.3.6.3.3. Italy
          • 5.3.6.3.4. United Kingdom
          • 5.3.6.3.5. Netherlands
          • 5.3.6.3.6. Rest of Europe
        • 5.3.6.4. MEA
          • 5.3.6.4.1. Middle East
          • 5.3.6.4.2. Africa
        • 5.3.6.5. North America
          • 5.3.6.5.1. United States
          • 5.3.6.5.2. Canada
          • 5.3.6.5.3. Mexico
    • 5.4. Global Rare Disease Drug (Price)
  • 6. Rare Disease Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Novartis (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bristol-Myers Squibb Company (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Celgene Corporation (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. F. Hoffmann-La Roche Ltd. (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Pfizer, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Sanofi S.A. (France)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Alexion Pharmaceuticals, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Eli Lilly and Company (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Novo Nordisk A/S (Denmark)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. AstraZeneca (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Eisai Co., Ltd. (Japan)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Daiichi Sankyo Company Limited (Japan)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Rare Disease Drug Sale, by Application, Disease, Form, Distribution Channel, Indication and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Rare Disease Drug (Value)
      • 7.2.1. Global Rare Disease Drug by: Application (Value)
        • 7.2.1.1. Hospitals
        • 7.2.1.2. Clinics
        • 7.2.1.3. Others
      • 7.2.2. Global Rare Disease Drug by: Disease (Value)
        • 7.2.2.1. Oncologic Diseases
        • 7.2.2.2. Metabolic Diseases
        • 7.2.2.3. Hematologic & Immunologic Diseases
        • 7.2.2.4. Infectious Diseases
        • 7.2.2.5. Neurologic Diseases
        • 7.2.2.6. Other Rare Diseases
      • 7.2.3. Global Rare Disease Drug by: Form (Value)
        • 7.2.3.1. Tablet
        • 7.2.3.2. Powder
        • 7.2.3.3. Injections
        • 7.2.3.4. Others
      • 7.2.4. Global Rare Disease Drug by: Distribution Channel (Value)
        • 7.2.4.1. Pharmacies
        • 7.2.4.2. Grocery Stores
        • 7.2.4.3. Internet Sales
        • 7.2.4.4. Mail Order
        • 7.2.4.5. Direct Marketing Routes
        • 7.2.4.6. Other Convenience Stores
      • 7.2.5. Global Rare Disease Drug by: Indication (Value)
        • 7.2.5.1. Non-Hodgkin Lymphoma
        • 7.2.5.2. Acute Myeloid Leukemia
        • 7.2.5.3. Cystic Fibrosis
        • 7.2.5.4. Glioma
        • 7.2.5.5. Pancreatic Cancer
        • 7.2.5.6. Ovarian Cancer
        • 7.2.5.7. Multiple Myeloma
        • 7.2.5.8. Duchenne Muscular Dystrophy
        • 7.2.5.9. Graft vs Host Disease
        • 7.2.5.10. Renal Cell Carcinoma
        • 7.2.5.11. Others
      • 7.2.6. Global Rare Disease Drug Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Rare Disease Drug (Volume)
      • 7.3.1. Global Rare Disease Drug by: Application (Volume)
        • 7.3.1.1. Hospitals
        • 7.3.1.2. Clinics
        • 7.3.1.3. Others
      • 7.3.2. Global Rare Disease Drug by: Disease (Volume)
        • 7.3.2.1. Oncologic Diseases
        • 7.3.2.2. Metabolic Diseases
        • 7.3.2.3. Hematologic & Immunologic Diseases
        • 7.3.2.4. Infectious Diseases
        • 7.3.2.5. Neurologic Diseases
        • 7.3.2.6. Other Rare Diseases
      • 7.3.3. Global Rare Disease Drug by: Form (Volume)
        • 7.3.3.1. Tablet
        • 7.3.3.2. Powder
        • 7.3.3.3. Injections
        • 7.3.3.4. Others
      • 7.3.4. Global Rare Disease Drug by: Distribution Channel (Volume)
        • 7.3.4.1. Pharmacies
        • 7.3.4.2. Grocery Stores
        • 7.3.4.3. Internet Sales
        • 7.3.4.4. Mail Order
        • 7.3.4.5. Direct Marketing Routes
        • 7.3.4.6. Other Convenience Stores
      • 7.3.5. Global Rare Disease Drug by: Indication (Volume)
        • 7.3.5.1. Non-Hodgkin Lymphoma
        • 7.3.5.2. Acute Myeloid Leukemia
        • 7.3.5.3. Cystic Fibrosis
        • 7.3.5.4. Glioma
        • 7.3.5.5. Pancreatic Cancer
        • 7.3.5.6. Ovarian Cancer
        • 7.3.5.7. Multiple Myeloma
        • 7.3.5.8. Duchenne Muscular Dystrophy
        • 7.3.5.9. Graft vs Host Disease
        • 7.3.5.10. Renal Cell Carcinoma
        • 7.3.5.11. Others
      • 7.3.6. Global Rare Disease Drug Region
        • 7.3.6.1. South America
          • 7.3.6.1.1. Brazil
          • 7.3.6.1.2. Argentina
          • 7.3.6.1.3. Rest of South America
        • 7.3.6.2. Asia Pacific
          • 7.3.6.2.1. China
          • 7.3.6.2.2. Japan
          • 7.3.6.2.3. India
          • 7.3.6.2.4. South Korea
          • 7.3.6.2.5. Taiwan
          • 7.3.6.2.6. Australia
          • 7.3.6.2.7. Rest of Asia-Pacific
        • 7.3.6.3. Europe
          • 7.3.6.3.1. Germany
          • 7.3.6.3.2. France
          • 7.3.6.3.3. Italy
          • 7.3.6.3.4. United Kingdom
          • 7.3.6.3.5. Netherlands
          • 7.3.6.3.6. Rest of Europe
        • 7.3.6.4. MEA
          • 7.3.6.4.1. Middle East
          • 7.3.6.4.2. Africa
        • 7.3.6.5. North America
          • 7.3.6.5.1. United States
          • 7.3.6.5.2. Canada
          • 7.3.6.5.3. Mexico
    • 7.4. Global Rare Disease Drug (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Rare Disease Drug: by Application(USD Million)
  • Table 2. Rare Disease Drug Hospitals , by Region USD Million (2018-2023)
  • Table 3. Rare Disease Drug Clinics , by Region USD Million (2018-2023)
  • Table 4. Rare Disease Drug Others , by Region USD Million (2018-2023)
  • Table 5. Rare Disease Drug: by Disease(USD Million)
  • Table 6. Rare Disease Drug Oncologic Diseases , by Region USD Million (2018-2023)
  • Table 7. Rare Disease Drug Metabolic Diseases , by Region USD Million (2018-2023)
  • Table 8. Rare Disease Drug Hematologic & Immunologic Diseases , by Region USD Million (2018-2023)
  • Table 9. Rare Disease Drug Infectious Diseases , by Region USD Million (2018-2023)
  • Table 10. Rare Disease Drug Neurologic Diseases , by Region USD Million (2018-2023)
  • Table 11. Rare Disease Drug Other Rare Diseases , by Region USD Million (2018-2023)
  • Table 12. Rare Disease Drug: by Form(USD Million)
  • Table 13. Rare Disease Drug Tablet , by Region USD Million (2018-2023)
  • Table 14. Rare Disease Drug Powder , by Region USD Million (2018-2023)
  • Table 15. Rare Disease Drug Injections , by Region USD Million (2018-2023)
  • Table 16. Rare Disease Drug Others , by Region USD Million (2018-2023)
  • Table 17. Rare Disease Drug: by Distribution Channel(USD Million)
  • Table 18. Rare Disease Drug Pharmacies , by Region USD Million (2018-2023)
  • Table 19. Rare Disease Drug Grocery Stores , by Region USD Million (2018-2023)
  • Table 20. Rare Disease Drug Internet Sales , by Region USD Million (2018-2023)
  • Table 21. Rare Disease Drug Mail Order , by Region USD Million (2018-2023)
  • Table 22. Rare Disease Drug Direct Marketing Routes , by Region USD Million (2018-2023)
  • Table 23. Rare Disease Drug Other Convenience Stores , by Region USD Million (2018-2023)
  • Table 24. Rare Disease Drug: by Indication(USD Million)
  • Table 25. Rare Disease Drug Non-Hodgkin Lymphoma , by Region USD Million (2018-2023)
  • Table 26. Rare Disease Drug Acute Myeloid Leukemia , by Region USD Million (2018-2023)
  • Table 27. Rare Disease Drug Cystic Fibrosis , by Region USD Million (2018-2023)
  • Table 28. Rare Disease Drug Glioma , by Region USD Million (2018-2023)
  • Table 29. Rare Disease Drug Pancreatic Cancer , by Region USD Million (2018-2023)
  • Table 30. Rare Disease Drug Ovarian Cancer , by Region USD Million (2018-2023)
  • Table 31. Rare Disease Drug Multiple Myeloma , by Region USD Million (2018-2023)
  • Table 32. Rare Disease Drug Duchenne Muscular Dystrophy , by Region USD Million (2018-2023)
  • Table 33. Rare Disease Drug Graft vs Host Disease , by Region USD Million (2018-2023)
  • Table 34. Rare Disease Drug Renal Cell Carcinoma , by Region USD Million (2018-2023)
  • Table 35. Rare Disease Drug Others , by Region USD Million (2018-2023)
  • Table 36. South America Rare Disease Drug, by Country USD Million (2018-2023)
  • Table 37. South America Rare Disease Drug, by Application USD Million (2018-2023)
  • Table 38. South America Rare Disease Drug, by Disease USD Million (2018-2023)
  • Table 39. South America Rare Disease Drug, by Form USD Million (2018-2023)
  • Table 40. South America Rare Disease Drug, by Distribution Channel USD Million (2018-2023)
  • Table 41. South America Rare Disease Drug, by Indication USD Million (2018-2023)
  • Table 42. Brazil Rare Disease Drug, by Application USD Million (2018-2023)
  • Table 43. Brazil Rare Disease Drug, by Disease USD Million (2018-2023)
  • Table 44. Brazil Rare Disease Drug, by Form USD Million (2018-2023)
  • Table 45. Brazil Rare Disease Drug, by Distribution Channel USD Million (2018-2023)
  • Table 46. Brazil Rare Disease Drug, by Indication USD Million (2018-2023)
  • Table 47. Argentina Rare Disease Drug, by Application USD Million (2018-2023)
  • Table 48. Argentina Rare Disease Drug, by Disease USD Million (2018-2023)
  • Table 49. Argentina Rare Disease Drug, by Form USD Million (2018-2023)
  • Table 50. Argentina Rare Disease Drug, by Distribution Channel USD Million (2018-2023)
  • Table 51. Argentina Rare Disease Drug, by Indication USD Million (2018-2023)
  • Table 52. Rest of South America Rare Disease Drug, by Application USD Million (2018-2023)
  • Table 53. Rest of South America Rare Disease Drug, by Disease USD Million (2018-2023)
  • Table 54. Rest of South America Rare Disease Drug, by Form USD Million (2018-2023)
  • Table 55. Rest of South America Rare Disease Drug, by Distribution Channel USD Million (2018-2023)
  • Table 56. Rest of South America Rare Disease Drug, by Indication USD Million (2018-2023)
  • Table 57. Asia Pacific Rare Disease Drug, by Country USD Million (2018-2023)
  • Table 58. Asia Pacific Rare Disease Drug, by Application USD Million (2018-2023)
  • Table 59. Asia Pacific Rare Disease Drug, by Disease USD Million (2018-2023)
  • Table 60. Asia Pacific Rare Disease Drug, by Form USD Million (2018-2023)
  • Table 61. Asia Pacific Rare Disease Drug, by Distribution Channel USD Million (2018-2023)
  • Table 62. Asia Pacific Rare Disease Drug, by Indication USD Million (2018-2023)
  • Table 63. China Rare Disease Drug, by Application USD Million (2018-2023)
  • Table 64. China Rare Disease Drug, by Disease USD Million (2018-2023)
  • Table 65. China Rare Disease Drug, by Form USD Million (2018-2023)
  • Table 66. China Rare Disease Drug, by Distribution Channel USD Million (2018-2023)
  • Table 67. China Rare Disease Drug, by Indication USD Million (2018-2023)
  • Table 68. Japan Rare Disease Drug, by Application USD Million (2018-2023)
  • Table 69. Japan Rare Disease Drug, by Disease USD Million (2018-2023)
  • Table 70. Japan Rare Disease Drug, by Form USD Million (2018-2023)
  • Table 71. Japan Rare Disease Drug, by Distribution Channel USD Million (2018-2023)
  • Table 72. Japan Rare Disease Drug, by Indication USD Million (2018-2023)
  • Table 73. India Rare Disease Drug, by Application USD Million (2018-2023)
  • Table 74. India Rare Disease Drug, by Disease USD Million (2018-2023)
  • Table 75. India Rare Disease Drug, by Form USD Million (2018-2023)
  • Table 76. India Rare Disease Drug, by Distribution Channel USD Million (2018-2023)
  • Table 77. India Rare Disease Drug, by Indication USD Million (2018-2023)
  • Table 78. South Korea Rare Disease Drug, by Application USD Million (2018-2023)
  • Table 79. South Korea Rare Disease Drug, by Disease USD Million (2018-2023)
  • Table 80. South Korea Rare Disease Drug, by Form USD Million (2018-2023)
  • Table 81. South Korea Rare Disease Drug, by Distribution Channel USD Million (2018-2023)
  • Table 82. South Korea Rare Disease Drug, by Indication USD Million (2018-2023)
  • Table 83. Taiwan Rare Disease Drug, by Application USD Million (2018-2023)
  • Table 84. Taiwan Rare Disease Drug, by Disease USD Million (2018-2023)
  • Table 85. Taiwan Rare Disease Drug, by Form USD Million (2018-2023)
  • Table 86. Taiwan Rare Disease Drug, by Distribution Channel USD Million (2018-2023)
  • Table 87. Taiwan Rare Disease Drug, by Indication USD Million (2018-2023)
  • Table 88. Australia Rare Disease Drug, by Application USD Million (2018-2023)
  • Table 89. Australia Rare Disease Drug, by Disease USD Million (2018-2023)
  • Table 90. Australia Rare Disease Drug, by Form USD Million (2018-2023)
  • Table 91. Australia Rare Disease Drug, by Distribution Channel USD Million (2018-2023)
  • Table 92. Australia Rare Disease Drug, by Indication USD Million (2018-2023)
  • Table 93. Rest of Asia-Pacific Rare Disease Drug, by Application USD Million (2018-2023)
  • Table 94. Rest of Asia-Pacific Rare Disease Drug, by Disease USD Million (2018-2023)
  • Table 95. Rest of Asia-Pacific Rare Disease Drug, by Form USD Million (2018-2023)
  • Table 96. Rest of Asia-Pacific Rare Disease Drug, by Distribution Channel USD Million (2018-2023)
  • Table 97. Rest of Asia-Pacific Rare Disease Drug, by Indication USD Million (2018-2023)
  • Table 98. Europe Rare Disease Drug, by Country USD Million (2018-2023)
  • Table 99. Europe Rare Disease Drug, by Application USD Million (2018-2023)
  • Table 100. Europe Rare Disease Drug, by Disease USD Million (2018-2023)
  • Table 101. Europe Rare Disease Drug, by Form USD Million (2018-2023)
  • Table 102. Europe Rare Disease Drug, by Distribution Channel USD Million (2018-2023)
  • Table 103. Europe Rare Disease Drug, by Indication USD Million (2018-2023)
  • Table 104. Germany Rare Disease Drug, by Application USD Million (2018-2023)
  • Table 105. Germany Rare Disease Drug, by Disease USD Million (2018-2023)
  • Table 106. Germany Rare Disease Drug, by Form USD Million (2018-2023)
  • Table 107. Germany Rare Disease Drug, by Distribution Channel USD Million (2018-2023)
  • Table 108. Germany Rare Disease Drug, by Indication USD Million (2018-2023)
  • Table 109. France Rare Disease Drug, by Application USD Million (2018-2023)
  • Table 110. France Rare Disease Drug, by Disease USD Million (2018-2023)
  • Table 111. France Rare Disease Drug, by Form USD Million (2018-2023)
  • Table 112. France Rare Disease Drug, by Distribution Channel USD Million (2018-2023)
  • Table 113. France Rare Disease Drug, by Indication USD Million (2018-2023)
  • Table 114. Italy Rare Disease Drug, by Application USD Million (2018-2023)
  • Table 115. Italy Rare Disease Drug, by Disease USD Million (2018-2023)
  • Table 116. Italy Rare Disease Drug, by Form USD Million (2018-2023)
  • Table 117. Italy Rare Disease Drug, by Distribution Channel USD Million (2018-2023)
  • Table 118. Italy Rare Disease Drug, by Indication USD Million (2018-2023)
  • Table 119. United Kingdom Rare Disease Drug, by Application USD Million (2018-2023)
  • Table 120. United Kingdom Rare Disease Drug, by Disease USD Million (2018-2023)
  • Table 121. United Kingdom Rare Disease Drug, by Form USD Million (2018-2023)
  • Table 122. United Kingdom Rare Disease Drug, by Distribution Channel USD Million (2018-2023)
  • Table 123. United Kingdom Rare Disease Drug, by Indication USD Million (2018-2023)
  • Table 124. Netherlands Rare Disease Drug, by Application USD Million (2018-2023)
  • Table 125. Netherlands Rare Disease Drug, by Disease USD Million (2018-2023)
  • Table 126. Netherlands Rare Disease Drug, by Form USD Million (2018-2023)
  • Table 127. Netherlands Rare Disease Drug, by Distribution Channel USD Million (2018-2023)
  • Table 128. Netherlands Rare Disease Drug, by Indication USD Million (2018-2023)
  • Table 129. Rest of Europe Rare Disease Drug, by Application USD Million (2018-2023)
  • Table 130. Rest of Europe Rare Disease Drug, by Disease USD Million (2018-2023)
  • Table 131. Rest of Europe Rare Disease Drug, by Form USD Million (2018-2023)
  • Table 132. Rest of Europe Rare Disease Drug, by Distribution Channel USD Million (2018-2023)
  • Table 133. Rest of Europe Rare Disease Drug, by Indication USD Million (2018-2023)
  • Table 134. MEA Rare Disease Drug, by Country USD Million (2018-2023)
  • Table 135. MEA Rare Disease Drug, by Application USD Million (2018-2023)
  • Table 136. MEA Rare Disease Drug, by Disease USD Million (2018-2023)
  • Table 137. MEA Rare Disease Drug, by Form USD Million (2018-2023)
  • Table 138. MEA Rare Disease Drug, by Distribution Channel USD Million (2018-2023)
  • Table 139. MEA Rare Disease Drug, by Indication USD Million (2018-2023)
  • Table 140. Middle East Rare Disease Drug, by Application USD Million (2018-2023)
  • Table 141. Middle East Rare Disease Drug, by Disease USD Million (2018-2023)
  • Table 142. Middle East Rare Disease Drug, by Form USD Million (2018-2023)
  • Table 143. Middle East Rare Disease Drug, by Distribution Channel USD Million (2018-2023)
  • Table 144. Middle East Rare Disease Drug, by Indication USD Million (2018-2023)
  • Table 145. Africa Rare Disease Drug, by Application USD Million (2018-2023)
  • Table 146. Africa Rare Disease Drug, by Disease USD Million (2018-2023)
  • Table 147. Africa Rare Disease Drug, by Form USD Million (2018-2023)
  • Table 148. Africa Rare Disease Drug, by Distribution Channel USD Million (2018-2023)
  • Table 149. Africa Rare Disease Drug, by Indication USD Million (2018-2023)
  • Table 150. North America Rare Disease Drug, by Country USD Million (2018-2023)
  • Table 151. North America Rare Disease Drug, by Application USD Million (2018-2023)
  • Table 152. North America Rare Disease Drug, by Disease USD Million (2018-2023)
  • Table 153. North America Rare Disease Drug, by Form USD Million (2018-2023)
  • Table 154. North America Rare Disease Drug, by Distribution Channel USD Million (2018-2023)
  • Table 155. North America Rare Disease Drug, by Indication USD Million (2018-2023)
  • Table 156. United States Rare Disease Drug, by Application USD Million (2018-2023)
  • Table 157. United States Rare Disease Drug, by Disease USD Million (2018-2023)
  • Table 158. United States Rare Disease Drug, by Form USD Million (2018-2023)
  • Table 159. United States Rare Disease Drug, by Distribution Channel USD Million (2018-2023)
  • Table 160. United States Rare Disease Drug, by Indication USD Million (2018-2023)
  • Table 161. Canada Rare Disease Drug, by Application USD Million (2018-2023)
  • Table 162. Canada Rare Disease Drug, by Disease USD Million (2018-2023)
  • Table 163. Canada Rare Disease Drug, by Form USD Million (2018-2023)
  • Table 164. Canada Rare Disease Drug, by Distribution Channel USD Million (2018-2023)
  • Table 165. Canada Rare Disease Drug, by Indication USD Million (2018-2023)
  • Table 166. Mexico Rare Disease Drug, by Application USD Million (2018-2023)
  • Table 167. Mexico Rare Disease Drug, by Disease USD Million (2018-2023)
  • Table 168. Mexico Rare Disease Drug, by Form USD Million (2018-2023)
  • Table 169. Mexico Rare Disease Drug, by Distribution Channel USD Million (2018-2023)
  • Table 170. Mexico Rare Disease Drug, by Indication USD Million (2018-2023)
  • Table 171. Rare Disease Drug Sales: by Application(K Units)
  • Table 172. Rare Disease Drug Sales Hospitals , by Region K Units (2018-2023)
  • Table 173. Rare Disease Drug Sales Clinics , by Region K Units (2018-2023)
  • Table 174. Rare Disease Drug Sales Others , by Region K Units (2018-2023)
  • Table 175. Rare Disease Drug Sales: by Disease(K Units)
  • Table 176. Rare Disease Drug Sales Oncologic Diseases , by Region K Units (2018-2023)
  • Table 177. Rare Disease Drug Sales Metabolic Diseases , by Region K Units (2018-2023)
  • Table 178. Rare Disease Drug Sales Hematologic & Immunologic Diseases , by Region K Units (2018-2023)
  • Table 179. Rare Disease Drug Sales Infectious Diseases , by Region K Units (2018-2023)
  • Table 180. Rare Disease Drug Sales Neurologic Diseases , by Region K Units (2018-2023)
  • Table 181. Rare Disease Drug Sales Other Rare Diseases , by Region K Units (2018-2023)
  • Table 182. Rare Disease Drug Sales: by Form(K Units)
  • Table 183. Rare Disease Drug Sales Tablet , by Region K Units (2018-2023)
  • Table 184. Rare Disease Drug Sales Powder , by Region K Units (2018-2023)
  • Table 185. Rare Disease Drug Sales Injections , by Region K Units (2018-2023)
  • Table 186. Rare Disease Drug Sales Others , by Region K Units (2018-2023)
  • Table 187. Rare Disease Drug Sales: by Distribution Channel(K Units)
  • Table 188. Rare Disease Drug Sales Pharmacies , by Region K Units (2018-2023)
  • Table 189. Rare Disease Drug Sales Grocery Stores , by Region K Units (2018-2023)
  • Table 190. Rare Disease Drug Sales Internet Sales , by Region K Units (2018-2023)
  • Table 191. Rare Disease Drug Sales Mail Order , by Region K Units (2018-2023)
  • Table 192. Rare Disease Drug Sales Direct Marketing Routes , by Region K Units (2018-2023)
  • Table 193. Rare Disease Drug Sales Other Convenience Stores , by Region K Units (2018-2023)
  • Table 194. Rare Disease Drug Sales: by Indication(K Units)
  • Table 195. Rare Disease Drug Sales Non-Hodgkin Lymphoma , by Region K Units (2018-2023)
  • Table 196. Rare Disease Drug Sales Acute Myeloid Leukemia , by Region K Units (2018-2023)
  • Table 197. Rare Disease Drug Sales Cystic Fibrosis , by Region K Units (2018-2023)
  • Table 198. Rare Disease Drug Sales Glioma , by Region K Units (2018-2023)
  • Table 199. Rare Disease Drug Sales Pancreatic Cancer , by Region K Units (2018-2023)
  • Table 200. Rare Disease Drug Sales Ovarian Cancer , by Region K Units (2018-2023)
  • Table 201. Rare Disease Drug Sales Multiple Myeloma , by Region K Units (2018-2023)
  • Table 202. Rare Disease Drug Sales Duchenne Muscular Dystrophy , by Region K Units (2018-2023)
  • Table 203. Rare Disease Drug Sales Graft vs Host Disease , by Region K Units (2018-2023)
  • Table 204. Rare Disease Drug Sales Renal Cell Carcinoma , by Region K Units (2018-2023)
  • Table 205. Rare Disease Drug Sales Others , by Region K Units (2018-2023)
  • Table 206. South America Rare Disease Drug Sales, by Country K Units (2018-2023)
  • Table 207. South America Rare Disease Drug Sales, by Application K Units (2018-2023)
  • Table 208. South America Rare Disease Drug Sales, by Disease K Units (2018-2023)
  • Table 209. South America Rare Disease Drug Sales, by Form K Units (2018-2023)
  • Table 210. South America Rare Disease Drug Sales, by Distribution Channel K Units (2018-2023)
  • Table 211. South America Rare Disease Drug Sales, by Indication K Units (2018-2023)
  • Table 212. Brazil Rare Disease Drug Sales, by Application K Units (2018-2023)
  • Table 213. Brazil Rare Disease Drug Sales, by Disease K Units (2018-2023)
  • Table 214. Brazil Rare Disease Drug Sales, by Form K Units (2018-2023)
  • Table 215. Brazil Rare Disease Drug Sales, by Distribution Channel K Units (2018-2023)
  • Table 216. Brazil Rare Disease Drug Sales, by Indication K Units (2018-2023)
  • Table 217. Argentina Rare Disease Drug Sales, by Application K Units (2018-2023)
  • Table 218. Argentina Rare Disease Drug Sales, by Disease K Units (2018-2023)
  • Table 219. Argentina Rare Disease Drug Sales, by Form K Units (2018-2023)
  • Table 220. Argentina Rare Disease Drug Sales, by Distribution Channel K Units (2018-2023)
  • Table 221. Argentina Rare Disease Drug Sales, by Indication K Units (2018-2023)
  • Table 222. Rest of South America Rare Disease Drug Sales, by Application K Units (2018-2023)
  • Table 223. Rest of South America Rare Disease Drug Sales, by Disease K Units (2018-2023)
  • Table 224. Rest of South America Rare Disease Drug Sales, by Form K Units (2018-2023)
  • Table 225. Rest of South America Rare Disease Drug Sales, by Distribution Channel K Units (2018-2023)
  • Table 226. Rest of South America Rare Disease Drug Sales, by Indication K Units (2018-2023)
  • Table 227. Asia Pacific Rare Disease Drug Sales, by Country K Units (2018-2023)
  • Table 228. Asia Pacific Rare Disease Drug Sales, by Application K Units (2018-2023)
  • Table 229. Asia Pacific Rare Disease Drug Sales, by Disease K Units (2018-2023)
  • Table 230. Asia Pacific Rare Disease Drug Sales, by Form K Units (2018-2023)
  • Table 231. Asia Pacific Rare Disease Drug Sales, by Distribution Channel K Units (2018-2023)
  • Table 232. Asia Pacific Rare Disease Drug Sales, by Indication K Units (2018-2023)
  • Table 233. China Rare Disease Drug Sales, by Application K Units (2018-2023)
  • Table 234. China Rare Disease Drug Sales, by Disease K Units (2018-2023)
  • Table 235. China Rare Disease Drug Sales, by Form K Units (2018-2023)
  • Table 236. China Rare Disease Drug Sales, by Distribution Channel K Units (2018-2023)
  • Table 237. China Rare Disease Drug Sales, by Indication K Units (2018-2023)
  • Table 238. Japan Rare Disease Drug Sales, by Application K Units (2018-2023)
  • Table 239. Japan Rare Disease Drug Sales, by Disease K Units (2018-2023)
  • Table 240. Japan Rare Disease Drug Sales, by Form K Units (2018-2023)
  • Table 241. Japan Rare Disease Drug Sales, by Distribution Channel K Units (2018-2023)
  • Table 242. Japan Rare Disease Drug Sales, by Indication K Units (2018-2023)
  • Table 243. India Rare Disease Drug Sales, by Application K Units (2018-2023)
  • Table 244. India Rare Disease Drug Sales, by Disease K Units (2018-2023)
  • Table 245. India Rare Disease Drug Sales, by Form K Units (2018-2023)
  • Table 246. India Rare Disease Drug Sales, by Distribution Channel K Units (2018-2023)
  • Table 247. India Rare Disease Drug Sales, by Indication K Units (2018-2023)
  • Table 248. South Korea Rare Disease Drug Sales, by Application K Units (2018-2023)
  • Table 249. South Korea Rare Disease Drug Sales, by Disease K Units (2018-2023)
  • Table 250. South Korea Rare Disease Drug Sales, by Form K Units (2018-2023)
  • Table 251. South Korea Rare Disease Drug Sales, by Distribution Channel K Units (2018-2023)
  • Table 252. South Korea Rare Disease Drug Sales, by Indication K Units (2018-2023)
  • Table 253. Taiwan Rare Disease Drug Sales, by Application K Units (2018-2023)
  • Table 254. Taiwan Rare Disease Drug Sales, by Disease K Units (2018-2023)
  • Table 255. Taiwan Rare Disease Drug Sales, by Form K Units (2018-2023)
  • Table 256. Taiwan Rare Disease Drug Sales, by Distribution Channel K Units (2018-2023)
  • Table 257. Taiwan Rare Disease Drug Sales, by Indication K Units (2018-2023)
  • Table 258. Australia Rare Disease Drug Sales, by Application K Units (2018-2023)
  • Table 259. Australia Rare Disease Drug Sales, by Disease K Units (2018-2023)
  • Table 260. Australia Rare Disease Drug Sales, by Form K Units (2018-2023)
  • Table 261. Australia Rare Disease Drug Sales, by Distribution Channel K Units (2018-2023)
  • Table 262. Australia Rare Disease Drug Sales, by Indication K Units (2018-2023)
  • Table 263. Rest of Asia-Pacific Rare Disease Drug Sales, by Application K Units (2018-2023)
  • Table 264. Rest of Asia-Pacific Rare Disease Drug Sales, by Disease K Units (2018-2023)
  • Table 265. Rest of Asia-Pacific Rare Disease Drug Sales, by Form K Units (2018-2023)
  • Table 266. Rest of Asia-Pacific Rare Disease Drug Sales, by Distribution Channel K Units (2018-2023)
  • Table 267. Rest of Asia-Pacific Rare Disease Drug Sales, by Indication K Units (2018-2023)
  • Table 268. Europe Rare Disease Drug Sales, by Country K Units (2018-2023)
  • Table 269. Europe Rare Disease Drug Sales, by Application K Units (2018-2023)
  • Table 270. Europe Rare Disease Drug Sales, by Disease K Units (2018-2023)
  • Table 271. Europe Rare Disease Drug Sales, by Form K Units (2018-2023)
  • Table 272. Europe Rare Disease Drug Sales, by Distribution Channel K Units (2018-2023)
  • Table 273. Europe Rare Disease Drug Sales, by Indication K Units (2018-2023)
  • Table 274. Germany Rare Disease Drug Sales, by Application K Units (2018-2023)
  • Table 275. Germany Rare Disease Drug Sales, by Disease K Units (2018-2023)
  • Table 276. Germany Rare Disease Drug Sales, by Form K Units (2018-2023)
  • Table 277. Germany Rare Disease Drug Sales, by Distribution Channel K Units (2018-2023)
  • Table 278. Germany Rare Disease Drug Sales, by Indication K Units (2018-2023)
  • Table 279. France Rare Disease Drug Sales, by Application K Units (2018-2023)
  • Table 280. France Rare Disease Drug Sales, by Disease K Units (2018-2023)
  • Table 281. France Rare Disease Drug Sales, by Form K Units (2018-2023)
  • Table 282. France Rare Disease Drug Sales, by Distribution Channel K Units (2018-2023)
  • Table 283. France Rare Disease Drug Sales, by Indication K Units (2018-2023)
  • Table 284. Italy Rare Disease Drug Sales, by Application K Units (2018-2023)
  • Table 285. Italy Rare Disease Drug Sales, by Disease K Units (2018-2023)
  • Table 286. Italy Rare Disease Drug Sales, by Form K Units (2018-2023)
  • Table 287. Italy Rare Disease Drug Sales, by Distribution Channel K Units (2018-2023)
  • Table 288. Italy Rare Disease Drug Sales, by Indication K Units (2018-2023)
  • Table 289. United Kingdom Rare Disease Drug Sales, by Application K Units (2018-2023)
  • Table 290. United Kingdom Rare Disease Drug Sales, by Disease K Units (2018-2023)
  • Table 291. United Kingdom Rare Disease Drug Sales, by Form K Units (2018-2023)
  • Table 292. United Kingdom Rare Disease Drug Sales, by Distribution Channel K Units (2018-2023)
  • Table 293. United Kingdom Rare Disease Drug Sales, by Indication K Units (2018-2023)
  • Table 294. Netherlands Rare Disease Drug Sales, by Application K Units (2018-2023)
  • Table 295. Netherlands Rare Disease Drug Sales, by Disease K Units (2018-2023)
  • Table 296. Netherlands Rare Disease Drug Sales, by Form K Units (2018-2023)
  • Table 297. Netherlands Rare Disease Drug Sales, by Distribution Channel K Units (2018-2023)
  • Table 298. Netherlands Rare Disease Drug Sales, by Indication K Units (2018-2023)
  • Table 299. Rest of Europe Rare Disease Drug Sales, by Application K Units (2018-2023)
  • Table 300. Rest of Europe Rare Disease Drug Sales, by Disease K Units (2018-2023)
  • Table 301. Rest of Europe Rare Disease Drug Sales, by Form K Units (2018-2023)
  • Table 302. Rest of Europe Rare Disease Drug Sales, by Distribution Channel K Units (2018-2023)
  • Table 303. Rest of Europe Rare Disease Drug Sales, by Indication K Units (2018-2023)
  • Table 304. MEA Rare Disease Drug Sales, by Country K Units (2018-2023)
  • Table 305. MEA Rare Disease Drug Sales, by Application K Units (2018-2023)
  • Table 306. MEA Rare Disease Drug Sales, by Disease K Units (2018-2023)
  • Table 307. MEA Rare Disease Drug Sales, by Form K Units (2018-2023)
  • Table 308. MEA Rare Disease Drug Sales, by Distribution Channel K Units (2018-2023)
  • Table 309. MEA Rare Disease Drug Sales, by Indication K Units (2018-2023)
  • Table 310. Middle East Rare Disease Drug Sales, by Application K Units (2018-2023)
  • Table 311. Middle East Rare Disease Drug Sales, by Disease K Units (2018-2023)
  • Table 312. Middle East Rare Disease Drug Sales, by Form K Units (2018-2023)
  • Table 313. Middle East Rare Disease Drug Sales, by Distribution Channel K Units (2018-2023)
  • Table 314. Middle East Rare Disease Drug Sales, by Indication K Units (2018-2023)
  • Table 315. Africa Rare Disease Drug Sales, by Application K Units (2018-2023)
  • Table 316. Africa Rare Disease Drug Sales, by Disease K Units (2018-2023)
  • Table 317. Africa Rare Disease Drug Sales, by Form K Units (2018-2023)
  • Table 318. Africa Rare Disease Drug Sales, by Distribution Channel K Units (2018-2023)
  • Table 319. Africa Rare Disease Drug Sales, by Indication K Units (2018-2023)
  • Table 320. North America Rare Disease Drug Sales, by Country K Units (2018-2023)
  • Table 321. North America Rare Disease Drug Sales, by Application K Units (2018-2023)
  • Table 322. North America Rare Disease Drug Sales, by Disease K Units (2018-2023)
  • Table 323. North America Rare Disease Drug Sales, by Form K Units (2018-2023)
  • Table 324. North America Rare Disease Drug Sales, by Distribution Channel K Units (2018-2023)
  • Table 325. North America Rare Disease Drug Sales, by Indication K Units (2018-2023)
  • Table 326. United States Rare Disease Drug Sales, by Application K Units (2018-2023)
  • Table 327. United States Rare Disease Drug Sales, by Disease K Units (2018-2023)
  • Table 328. United States Rare Disease Drug Sales, by Form K Units (2018-2023)
  • Table 329. United States Rare Disease Drug Sales, by Distribution Channel K Units (2018-2023)
  • Table 330. United States Rare Disease Drug Sales, by Indication K Units (2018-2023)
  • Table 331. Canada Rare Disease Drug Sales, by Application K Units (2018-2023)
  • Table 332. Canada Rare Disease Drug Sales, by Disease K Units (2018-2023)
  • Table 333. Canada Rare Disease Drug Sales, by Form K Units (2018-2023)
  • Table 334. Canada Rare Disease Drug Sales, by Distribution Channel K Units (2018-2023)
  • Table 335. Canada Rare Disease Drug Sales, by Indication K Units (2018-2023)
  • Table 336. Mexico Rare Disease Drug Sales, by Application K Units (2018-2023)
  • Table 337. Mexico Rare Disease Drug Sales, by Disease K Units (2018-2023)
  • Table 338. Mexico Rare Disease Drug Sales, by Form K Units (2018-2023)
  • Table 339. Mexico Rare Disease Drug Sales, by Distribution Channel K Units (2018-2023)
  • Table 340. Mexico Rare Disease Drug Sales, by Indication K Units (2018-2023)
  • Table 341. Company Basic Information, Sales Area and Its Competitors
  • Table 342. Company Basic Information, Sales Area and Its Competitors
  • Table 343. Company Basic Information, Sales Area and Its Competitors
  • Table 344. Company Basic Information, Sales Area and Its Competitors
  • Table 345. Company Basic Information, Sales Area and Its Competitors
  • Table 346. Company Basic Information, Sales Area and Its Competitors
  • Table 347. Company Basic Information, Sales Area and Its Competitors
  • Table 348. Company Basic Information, Sales Area and Its Competitors
  • Table 349. Company Basic Information, Sales Area and Its Competitors
  • Table 350. Company Basic Information, Sales Area and Its Competitors
  • Table 351. Company Basic Information, Sales Area and Its Competitors
  • Table 352. Company Basic Information, Sales Area and Its Competitors
  • Table 353. Rare Disease Drug: by Application(USD Million)
  • Table 354. Rare Disease Drug Hospitals , by Region USD Million (2025-2030)
  • Table 355. Rare Disease Drug Clinics , by Region USD Million (2025-2030)
  • Table 356. Rare Disease Drug Others , by Region USD Million (2025-2030)
  • Table 357. Rare Disease Drug: by Disease(USD Million)
  • Table 358. Rare Disease Drug Oncologic Diseases , by Region USD Million (2025-2030)
  • Table 359. Rare Disease Drug Metabolic Diseases , by Region USD Million (2025-2030)
  • Table 360. Rare Disease Drug Hematologic & Immunologic Diseases , by Region USD Million (2025-2030)
  • Table 361. Rare Disease Drug Infectious Diseases , by Region USD Million (2025-2030)
  • Table 362. Rare Disease Drug Neurologic Diseases , by Region USD Million (2025-2030)
  • Table 363. Rare Disease Drug Other Rare Diseases , by Region USD Million (2025-2030)
  • Table 364. Rare Disease Drug: by Form(USD Million)
  • Table 365. Rare Disease Drug Tablet , by Region USD Million (2025-2030)
  • Table 366. Rare Disease Drug Powder , by Region USD Million (2025-2030)
  • Table 367. Rare Disease Drug Injections , by Region USD Million (2025-2030)
  • Table 368. Rare Disease Drug Others , by Region USD Million (2025-2030)
  • Table 369. Rare Disease Drug: by Distribution Channel(USD Million)
  • Table 370. Rare Disease Drug Pharmacies , by Region USD Million (2025-2030)
  • Table 371. Rare Disease Drug Grocery Stores , by Region USD Million (2025-2030)
  • Table 372. Rare Disease Drug Internet Sales , by Region USD Million (2025-2030)
  • Table 373. Rare Disease Drug Mail Order , by Region USD Million (2025-2030)
  • Table 374. Rare Disease Drug Direct Marketing Routes , by Region USD Million (2025-2030)
  • Table 375. Rare Disease Drug Other Convenience Stores , by Region USD Million (2025-2030)
  • Table 376. Rare Disease Drug: by Indication(USD Million)
  • Table 377. Rare Disease Drug Non-Hodgkin Lymphoma , by Region USD Million (2025-2030)
  • Table 378. Rare Disease Drug Acute Myeloid Leukemia , by Region USD Million (2025-2030)
  • Table 379. Rare Disease Drug Cystic Fibrosis , by Region USD Million (2025-2030)
  • Table 380. Rare Disease Drug Glioma , by Region USD Million (2025-2030)
  • Table 381. Rare Disease Drug Pancreatic Cancer , by Region USD Million (2025-2030)
  • Table 382. Rare Disease Drug Ovarian Cancer , by Region USD Million (2025-2030)
  • Table 383. Rare Disease Drug Multiple Myeloma , by Region USD Million (2025-2030)
  • Table 384. Rare Disease Drug Duchenne Muscular Dystrophy , by Region USD Million (2025-2030)
  • Table 385. Rare Disease Drug Graft vs Host Disease , by Region USD Million (2025-2030)
  • Table 386. Rare Disease Drug Renal Cell Carcinoma , by Region USD Million (2025-2030)
  • Table 387. Rare Disease Drug Others , by Region USD Million (2025-2030)
  • Table 388. South America Rare Disease Drug, by Country USD Million (2025-2030)
  • Table 389. South America Rare Disease Drug, by Application USD Million (2025-2030)
  • Table 390. South America Rare Disease Drug, by Disease USD Million (2025-2030)
  • Table 391. South America Rare Disease Drug, by Form USD Million (2025-2030)
  • Table 392. South America Rare Disease Drug, by Distribution Channel USD Million (2025-2030)
  • Table 393. South America Rare Disease Drug, by Indication USD Million (2025-2030)
  • Table 394. Brazil Rare Disease Drug, by Application USD Million (2025-2030)
  • Table 395. Brazil Rare Disease Drug, by Disease USD Million (2025-2030)
  • Table 396. Brazil Rare Disease Drug, by Form USD Million (2025-2030)
  • Table 397. Brazil Rare Disease Drug, by Distribution Channel USD Million (2025-2030)
  • Table 398. Brazil Rare Disease Drug, by Indication USD Million (2025-2030)
  • Table 399. Argentina Rare Disease Drug, by Application USD Million (2025-2030)
  • Table 400. Argentina Rare Disease Drug, by Disease USD Million (2025-2030)
  • Table 401. Argentina Rare Disease Drug, by Form USD Million (2025-2030)
  • Table 402. Argentina Rare Disease Drug, by Distribution Channel USD Million (2025-2030)
  • Table 403. Argentina Rare Disease Drug, by Indication USD Million (2025-2030)
  • Table 404. Rest of South America Rare Disease Drug, by Application USD Million (2025-2030)
  • Table 405. Rest of South America Rare Disease Drug, by Disease USD Million (2025-2030)
  • Table 406. Rest of South America Rare Disease Drug, by Form USD Million (2025-2030)
  • Table 407. Rest of South America Rare Disease Drug, by Distribution Channel USD Million (2025-2030)
  • Table 408. Rest of South America Rare Disease Drug, by Indication USD Million (2025-2030)
  • Table 409. Asia Pacific Rare Disease Drug, by Country USD Million (2025-2030)
  • Table 410. Asia Pacific Rare Disease Drug, by Application USD Million (2025-2030)
  • Table 411. Asia Pacific Rare Disease Drug, by Disease USD Million (2025-2030)
  • Table 412. Asia Pacific Rare Disease Drug, by Form USD Million (2025-2030)
  • Table 413. Asia Pacific Rare Disease Drug, by Distribution Channel USD Million (2025-2030)
  • Table 414. Asia Pacific Rare Disease Drug, by Indication USD Million (2025-2030)
  • Table 415. China Rare Disease Drug, by Application USD Million (2025-2030)
  • Table 416. China Rare Disease Drug, by Disease USD Million (2025-2030)
  • Table 417. China Rare Disease Drug, by Form USD Million (2025-2030)
  • Table 418. China Rare Disease Drug, by Distribution Channel USD Million (2025-2030)
  • Table 419. China Rare Disease Drug, by Indication USD Million (2025-2030)
  • Table 420. Japan Rare Disease Drug, by Application USD Million (2025-2030)
  • Table 421. Japan Rare Disease Drug, by Disease USD Million (2025-2030)
  • Table 422. Japan Rare Disease Drug, by Form USD Million (2025-2030)
  • Table 423. Japan Rare Disease Drug, by Distribution Channel USD Million (2025-2030)
  • Table 424. Japan Rare Disease Drug, by Indication USD Million (2025-2030)
  • Table 425. India Rare Disease Drug, by Application USD Million (2025-2030)
  • Table 426. India Rare Disease Drug, by Disease USD Million (2025-2030)
  • Table 427. India Rare Disease Drug, by Form USD Million (2025-2030)
  • Table 428. India Rare Disease Drug, by Distribution Channel USD Million (2025-2030)
  • Table 429. India Rare Disease Drug, by Indication USD Million (2025-2030)
  • Table 430. South Korea Rare Disease Drug, by Application USD Million (2025-2030)
  • Table 431. South Korea Rare Disease Drug, by Disease USD Million (2025-2030)
  • Table 432. South Korea Rare Disease Drug, by Form USD Million (2025-2030)
  • Table 433. South Korea Rare Disease Drug, by Distribution Channel USD Million (2025-2030)
  • Table 434. South Korea Rare Disease Drug, by Indication USD Million (2025-2030)
  • Table 435. Taiwan Rare Disease Drug, by Application USD Million (2025-2030)
  • Table 436. Taiwan Rare Disease Drug, by Disease USD Million (2025-2030)
  • Table 437. Taiwan Rare Disease Drug, by Form USD Million (2025-2030)
  • Table 438. Taiwan Rare Disease Drug, by Distribution Channel USD Million (2025-2030)
  • Table 439. Taiwan Rare Disease Drug, by Indication USD Million (2025-2030)
  • Table 440. Australia Rare Disease Drug, by Application USD Million (2025-2030)
  • Table 441. Australia Rare Disease Drug, by Disease USD Million (2025-2030)
  • Table 442. Australia Rare Disease Drug, by Form USD Million (2025-2030)
  • Table 443. Australia Rare Disease Drug, by Distribution Channel USD Million (2025-2030)
  • Table 444. Australia Rare Disease Drug, by Indication USD Million (2025-2030)
  • Table 445. Rest of Asia-Pacific Rare Disease Drug, by Application USD Million (2025-2030)
  • Table 446. Rest of Asia-Pacific Rare Disease Drug, by Disease USD Million (2025-2030)
  • Table 447. Rest of Asia-Pacific Rare Disease Drug, by Form USD Million (2025-2030)
  • Table 448. Rest of Asia-Pacific Rare Disease Drug, by Distribution Channel USD Million (2025-2030)
  • Table 449. Rest of Asia-Pacific Rare Disease Drug, by Indication USD Million (2025-2030)
  • Table 450. Europe Rare Disease Drug, by Country USD Million (2025-2030)
  • Table 451. Europe Rare Disease Drug, by Application USD Million (2025-2030)
  • Table 452. Europe Rare Disease Drug, by Disease USD Million (2025-2030)
  • Table 453. Europe Rare Disease Drug, by Form USD Million (2025-2030)
  • Table 454. Europe Rare Disease Drug, by Distribution Channel USD Million (2025-2030)
  • Table 455. Europe Rare Disease Drug, by Indication USD Million (2025-2030)
  • Table 456. Germany Rare Disease Drug, by Application USD Million (2025-2030)
  • Table 457. Germany Rare Disease Drug, by Disease USD Million (2025-2030)
  • Table 458. Germany Rare Disease Drug, by Form USD Million (2025-2030)
  • Table 459. Germany Rare Disease Drug, by Distribution Channel USD Million (2025-2030)
  • Table 460. Germany Rare Disease Drug, by Indication USD Million (2025-2030)
  • Table 461. France Rare Disease Drug, by Application USD Million (2025-2030)
  • Table 462. France Rare Disease Drug, by Disease USD Million (2025-2030)
  • Table 463. France Rare Disease Drug, by Form USD Million (2025-2030)
  • Table 464. France Rare Disease Drug, by Distribution Channel USD Million (2025-2030)
  • Table 465. France Rare Disease Drug, by Indication USD Million (2025-2030)
  • Table 466. Italy Rare Disease Drug, by Application USD Million (2025-2030)
  • Table 467. Italy Rare Disease Drug, by Disease USD Million (2025-2030)
  • Table 468. Italy Rare Disease Drug, by Form USD Million (2025-2030)
  • Table 469. Italy Rare Disease Drug, by Distribution Channel USD Million (2025-2030)
  • Table 470. Italy Rare Disease Drug, by Indication USD Million (2025-2030)
  • Table 471. United Kingdom Rare Disease Drug, by Application USD Million (2025-2030)
  • Table 472. United Kingdom Rare Disease Drug, by Disease USD Million (2025-2030)
  • Table 473. United Kingdom Rare Disease Drug, by Form USD Million (2025-2030)
  • Table 474. United Kingdom Rare Disease Drug, by Distribution Channel USD Million (2025-2030)
  • Table 475. United Kingdom Rare Disease Drug, by Indication USD Million (2025-2030)
  • Table 476. Netherlands Rare Disease Drug, by Application USD Million (2025-2030)
  • Table 477. Netherlands Rare Disease Drug, by Disease USD Million (2025-2030)
  • Table 478. Netherlands Rare Disease Drug, by Form USD Million (2025-2030)
  • Table 479. Netherlands Rare Disease Drug, by Distribution Channel USD Million (2025-2030)
  • Table 480. Netherlands Rare Disease Drug, by Indication USD Million (2025-2030)
  • Table 481. Rest of Europe Rare Disease Drug, by Application USD Million (2025-2030)
  • Table 482. Rest of Europe Rare Disease Drug, by Disease USD Million (2025-2030)
  • Table 483. Rest of Europe Rare Disease Drug, by Form USD Million (2025-2030)
  • Table 484. Rest of Europe Rare Disease Drug, by Distribution Channel USD Million (2025-2030)
  • Table 485. Rest of Europe Rare Disease Drug, by Indication USD Million (2025-2030)
  • Table 486. MEA Rare Disease Drug, by Country USD Million (2025-2030)
  • Table 487. MEA Rare Disease Drug, by Application USD Million (2025-2030)
  • Table 488. MEA Rare Disease Drug, by Disease USD Million (2025-2030)
  • Table 489. MEA Rare Disease Drug, by Form USD Million (2025-2030)
  • Table 490. MEA Rare Disease Drug, by Distribution Channel USD Million (2025-2030)
  • Table 491. MEA Rare Disease Drug, by Indication USD Million (2025-2030)
  • Table 492. Middle East Rare Disease Drug, by Application USD Million (2025-2030)
  • Table 493. Middle East Rare Disease Drug, by Disease USD Million (2025-2030)
  • Table 494. Middle East Rare Disease Drug, by Form USD Million (2025-2030)
  • Table 495. Middle East Rare Disease Drug, by Distribution Channel USD Million (2025-2030)
  • Table 496. Middle East Rare Disease Drug, by Indication USD Million (2025-2030)
  • Table 497. Africa Rare Disease Drug, by Application USD Million (2025-2030)
  • Table 498. Africa Rare Disease Drug, by Disease USD Million (2025-2030)
  • Table 499. Africa Rare Disease Drug, by Form USD Million (2025-2030)
  • Table 500. Africa Rare Disease Drug, by Distribution Channel USD Million (2025-2030)
  • Table 501. Africa Rare Disease Drug, by Indication USD Million (2025-2030)
  • Table 502. North America Rare Disease Drug, by Country USD Million (2025-2030)
  • Table 503. North America Rare Disease Drug, by Application USD Million (2025-2030)
  • Table 504. North America Rare Disease Drug, by Disease USD Million (2025-2030)
  • Table 505. North America Rare Disease Drug, by Form USD Million (2025-2030)
  • Table 506. North America Rare Disease Drug, by Distribution Channel USD Million (2025-2030)
  • Table 507. North America Rare Disease Drug, by Indication USD Million (2025-2030)
  • Table 508. United States Rare Disease Drug, by Application USD Million (2025-2030)
  • Table 509. United States Rare Disease Drug, by Disease USD Million (2025-2030)
  • Table 510. United States Rare Disease Drug, by Form USD Million (2025-2030)
  • Table 511. United States Rare Disease Drug, by Distribution Channel USD Million (2025-2030)
  • Table 512. United States Rare Disease Drug, by Indication USD Million (2025-2030)
  • Table 513. Canada Rare Disease Drug, by Application USD Million (2025-2030)
  • Table 514. Canada Rare Disease Drug, by Disease USD Million (2025-2030)
  • Table 515. Canada Rare Disease Drug, by Form USD Million (2025-2030)
  • Table 516. Canada Rare Disease Drug, by Distribution Channel USD Million (2025-2030)
  • Table 517. Canada Rare Disease Drug, by Indication USD Million (2025-2030)
  • Table 518. Mexico Rare Disease Drug, by Application USD Million (2025-2030)
  • Table 519. Mexico Rare Disease Drug, by Disease USD Million (2025-2030)
  • Table 520. Mexico Rare Disease Drug, by Form USD Million (2025-2030)
  • Table 521. Mexico Rare Disease Drug, by Distribution Channel USD Million (2025-2030)
  • Table 522. Mexico Rare Disease Drug, by Indication USD Million (2025-2030)
  • Table 523. Rare Disease Drug Sales: by Application(K Units)
  • Table 524. Rare Disease Drug Sales Hospitals , by Region K Units (2025-2030)
  • Table 525. Rare Disease Drug Sales Clinics , by Region K Units (2025-2030)
  • Table 526. Rare Disease Drug Sales Others , by Region K Units (2025-2030)
  • Table 527. Rare Disease Drug Sales: by Disease(K Units)
  • Table 528. Rare Disease Drug Sales Oncologic Diseases , by Region K Units (2025-2030)
  • Table 529. Rare Disease Drug Sales Metabolic Diseases , by Region K Units (2025-2030)
  • Table 530. Rare Disease Drug Sales Hematologic & Immunologic Diseases , by Region K Units (2025-2030)
  • Table 531. Rare Disease Drug Sales Infectious Diseases , by Region K Units (2025-2030)
  • Table 532. Rare Disease Drug Sales Neurologic Diseases , by Region K Units (2025-2030)
  • Table 533. Rare Disease Drug Sales Other Rare Diseases , by Region K Units (2025-2030)
  • Table 534. Rare Disease Drug Sales: by Form(K Units)
  • Table 535. Rare Disease Drug Sales Tablet , by Region K Units (2025-2030)
  • Table 536. Rare Disease Drug Sales Powder , by Region K Units (2025-2030)
  • Table 537. Rare Disease Drug Sales Injections , by Region K Units (2025-2030)
  • Table 538. Rare Disease Drug Sales Others , by Region K Units (2025-2030)
  • Table 539. Rare Disease Drug Sales: by Distribution Channel(K Units)
  • Table 540. Rare Disease Drug Sales Pharmacies , by Region K Units (2025-2030)
  • Table 541. Rare Disease Drug Sales Grocery Stores , by Region K Units (2025-2030)
  • Table 542. Rare Disease Drug Sales Internet Sales , by Region K Units (2025-2030)
  • Table 543. Rare Disease Drug Sales Mail Order , by Region K Units (2025-2030)
  • Table 544. Rare Disease Drug Sales Direct Marketing Routes , by Region K Units (2025-2030)
  • Table 545. Rare Disease Drug Sales Other Convenience Stores , by Region K Units (2025-2030)
  • Table 546. Rare Disease Drug Sales: by Indication(K Units)
  • Table 547. Rare Disease Drug Sales Non-Hodgkin Lymphoma , by Region K Units (2025-2030)
  • Table 548. Rare Disease Drug Sales Acute Myeloid Leukemia , by Region K Units (2025-2030)
  • Table 549. Rare Disease Drug Sales Cystic Fibrosis , by Region K Units (2025-2030)
  • Table 550. Rare Disease Drug Sales Glioma , by Region K Units (2025-2030)
  • Table 551. Rare Disease Drug Sales Pancreatic Cancer , by Region K Units (2025-2030)
  • Table 552. Rare Disease Drug Sales Ovarian Cancer , by Region K Units (2025-2030)
  • Table 553. Rare Disease Drug Sales Multiple Myeloma , by Region K Units (2025-2030)
  • Table 554. Rare Disease Drug Sales Duchenne Muscular Dystrophy , by Region K Units (2025-2030)
  • Table 555. Rare Disease Drug Sales Graft vs Host Disease , by Region K Units (2025-2030)
  • Table 556. Rare Disease Drug Sales Renal Cell Carcinoma , by Region K Units (2025-2030)
  • Table 557. Rare Disease Drug Sales Others , by Region K Units (2025-2030)
  • Table 558. South America Rare Disease Drug Sales, by Country K Units (2025-2030)
  • Table 559. South America Rare Disease Drug Sales, by Application K Units (2025-2030)
  • Table 560. South America Rare Disease Drug Sales, by Disease K Units (2025-2030)
  • Table 561. South America Rare Disease Drug Sales, by Form K Units (2025-2030)
  • Table 562. South America Rare Disease Drug Sales, by Distribution Channel K Units (2025-2030)
  • Table 563. South America Rare Disease Drug Sales, by Indication K Units (2025-2030)
  • Table 564. Brazil Rare Disease Drug Sales, by Application K Units (2025-2030)
  • Table 565. Brazil Rare Disease Drug Sales, by Disease K Units (2025-2030)
  • Table 566. Brazil Rare Disease Drug Sales, by Form K Units (2025-2030)
  • Table 567. Brazil Rare Disease Drug Sales, by Distribution Channel K Units (2025-2030)
  • Table 568. Brazil Rare Disease Drug Sales, by Indication K Units (2025-2030)
  • Table 569. Argentina Rare Disease Drug Sales, by Application K Units (2025-2030)
  • Table 570. Argentina Rare Disease Drug Sales, by Disease K Units (2025-2030)
  • Table 571. Argentina Rare Disease Drug Sales, by Form K Units (2025-2030)
  • Table 572. Argentina Rare Disease Drug Sales, by Distribution Channel K Units (2025-2030)
  • Table 573. Argentina Rare Disease Drug Sales, by Indication K Units (2025-2030)
  • Table 574. Rest of South America Rare Disease Drug Sales, by Application K Units (2025-2030)
  • Table 575. Rest of South America Rare Disease Drug Sales, by Disease K Units (2025-2030)
  • Table 576. Rest of South America Rare Disease Drug Sales, by Form K Units (2025-2030)
  • Table 577. Rest of South America Rare Disease Drug Sales, by Distribution Channel K Units (2025-2030)
  • Table 578. Rest of South America Rare Disease Drug Sales, by Indication K Units (2025-2030)
  • Table 579. Asia Pacific Rare Disease Drug Sales, by Country K Units (2025-2030)
  • Table 580. Asia Pacific Rare Disease Drug Sales, by Application K Units (2025-2030)
  • Table 581. Asia Pacific Rare Disease Drug Sales, by Disease K Units (2025-2030)
  • Table 582. Asia Pacific Rare Disease Drug Sales, by Form K Units (2025-2030)
  • Table 583. Asia Pacific Rare Disease Drug Sales, by Distribution Channel K Units (2025-2030)
  • Table 584. Asia Pacific Rare Disease Drug Sales, by Indication K Units (2025-2030)
  • Table 585. China Rare Disease Drug Sales, by Application K Units (2025-2030)
  • Table 586. China Rare Disease Drug Sales, by Disease K Units (2025-2030)
  • Table 587. China Rare Disease Drug Sales, by Form K Units (2025-2030)
  • Table 588. China Rare Disease Drug Sales, by Distribution Channel K Units (2025-2030)
  • Table 589. China Rare Disease Drug Sales, by Indication K Units (2025-2030)
  • Table 590. Japan Rare Disease Drug Sales, by Application K Units (2025-2030)
  • Table 591. Japan Rare Disease Drug Sales, by Disease K Units (2025-2030)
  • Table 592. Japan Rare Disease Drug Sales, by Form K Units (2025-2030)
  • Table 593. Japan Rare Disease Drug Sales, by Distribution Channel K Units (2025-2030)
  • Table 594. Japan Rare Disease Drug Sales, by Indication K Units (2025-2030)
  • Table 595. India Rare Disease Drug Sales, by Application K Units (2025-2030)
  • Table 596. India Rare Disease Drug Sales, by Disease K Units (2025-2030)
  • Table 597. India Rare Disease Drug Sales, by Form K Units (2025-2030)
  • Table 598. India Rare Disease Drug Sales, by Distribution Channel K Units (2025-2030)
  • Table 599. India Rare Disease Drug Sales, by Indication K Units (2025-2030)
  • Table 600. South Korea Rare Disease Drug Sales, by Application K Units (2025-2030)
  • Table 601. South Korea Rare Disease Drug Sales, by Disease K Units (2025-2030)
  • Table 602. South Korea Rare Disease Drug Sales, by Form K Units (2025-2030)
  • Table 603. South Korea Rare Disease Drug Sales, by Distribution Channel K Units (2025-2030)
  • Table 604. South Korea Rare Disease Drug Sales, by Indication K Units (2025-2030)
  • Table 605. Taiwan Rare Disease Drug Sales, by Application K Units (2025-2030)
  • Table 606. Taiwan Rare Disease Drug Sales, by Disease K Units (2025-2030)
  • Table 607. Taiwan Rare Disease Drug Sales, by Form K Units (2025-2030)
  • Table 608. Taiwan Rare Disease Drug Sales, by Distribution Channel K Units (2025-2030)
  • Table 609. Taiwan Rare Disease Drug Sales, by Indication K Units (2025-2030)
  • Table 610. Australia Rare Disease Drug Sales, by Application K Units (2025-2030)
  • Table 611. Australia Rare Disease Drug Sales, by Disease K Units (2025-2030)
  • Table 612. Australia Rare Disease Drug Sales, by Form K Units (2025-2030)
  • Table 613. Australia Rare Disease Drug Sales, by Distribution Channel K Units (2025-2030)
  • Table 614. Australia Rare Disease Drug Sales, by Indication K Units (2025-2030)
  • Table 615. Rest of Asia-Pacific Rare Disease Drug Sales, by Application K Units (2025-2030)
  • Table 616. Rest of Asia-Pacific Rare Disease Drug Sales, by Disease K Units (2025-2030)
  • Table 617. Rest of Asia-Pacific Rare Disease Drug Sales, by Form K Units (2025-2030)
  • Table 618. Rest of Asia-Pacific Rare Disease Drug Sales, by Distribution Channel K Units (2025-2030)
  • Table 619. Rest of Asia-Pacific Rare Disease Drug Sales, by Indication K Units (2025-2030)
  • Table 620. Europe Rare Disease Drug Sales, by Country K Units (2025-2030)
  • Table 621. Europe Rare Disease Drug Sales, by Application K Units (2025-2030)
  • Table 622. Europe Rare Disease Drug Sales, by Disease K Units (2025-2030)
  • Table 623. Europe Rare Disease Drug Sales, by Form K Units (2025-2030)
  • Table 624. Europe Rare Disease Drug Sales, by Distribution Channel K Units (2025-2030)
  • Table 625. Europe Rare Disease Drug Sales, by Indication K Units (2025-2030)
  • Table 626. Germany Rare Disease Drug Sales, by Application K Units (2025-2030)
  • Table 627. Germany Rare Disease Drug Sales, by Disease K Units (2025-2030)
  • Table 628. Germany Rare Disease Drug Sales, by Form K Units (2025-2030)
  • Table 629. Germany Rare Disease Drug Sales, by Distribution Channel K Units (2025-2030)
  • Table 630. Germany Rare Disease Drug Sales, by Indication K Units (2025-2030)
  • Table 631. France Rare Disease Drug Sales, by Application K Units (2025-2030)
  • Table 632. France Rare Disease Drug Sales, by Disease K Units (2025-2030)
  • Table 633. France Rare Disease Drug Sales, by Form K Units (2025-2030)
  • Table 634. France Rare Disease Drug Sales, by Distribution Channel K Units (2025-2030)
  • Table 635. France Rare Disease Drug Sales, by Indication K Units (2025-2030)
  • Table 636. Italy Rare Disease Drug Sales, by Application K Units (2025-2030)
  • Table 637. Italy Rare Disease Drug Sales, by Disease K Units (2025-2030)
  • Table 638. Italy Rare Disease Drug Sales, by Form K Units (2025-2030)
  • Table 639. Italy Rare Disease Drug Sales, by Distribution Channel K Units (2025-2030)
  • Table 640. Italy Rare Disease Drug Sales, by Indication K Units (2025-2030)
  • Table 641. United Kingdom Rare Disease Drug Sales, by Application K Units (2025-2030)
  • Table 642. United Kingdom Rare Disease Drug Sales, by Disease K Units (2025-2030)
  • Table 643. United Kingdom Rare Disease Drug Sales, by Form K Units (2025-2030)
  • Table 644. United Kingdom Rare Disease Drug Sales, by Distribution Channel K Units (2025-2030)
  • Table 645. United Kingdom Rare Disease Drug Sales, by Indication K Units (2025-2030)
  • Table 646. Netherlands Rare Disease Drug Sales, by Application K Units (2025-2030)
  • Table 647. Netherlands Rare Disease Drug Sales, by Disease K Units (2025-2030)
  • Table 648. Netherlands Rare Disease Drug Sales, by Form K Units (2025-2030)
  • Table 649. Netherlands Rare Disease Drug Sales, by Distribution Channel K Units (2025-2030)
  • Table 650. Netherlands Rare Disease Drug Sales, by Indication K Units (2025-2030)
  • Table 651. Rest of Europe Rare Disease Drug Sales, by Application K Units (2025-2030)
  • Table 652. Rest of Europe Rare Disease Drug Sales, by Disease K Units (2025-2030)
  • Table 653. Rest of Europe Rare Disease Drug Sales, by Form K Units (2025-2030)
  • Table 654. Rest of Europe Rare Disease Drug Sales, by Distribution Channel K Units (2025-2030)
  • Table 655. Rest of Europe Rare Disease Drug Sales, by Indication K Units (2025-2030)
  • Table 656. MEA Rare Disease Drug Sales, by Country K Units (2025-2030)
  • Table 657. MEA Rare Disease Drug Sales, by Application K Units (2025-2030)
  • Table 658. MEA Rare Disease Drug Sales, by Disease K Units (2025-2030)
  • Table 659. MEA Rare Disease Drug Sales, by Form K Units (2025-2030)
  • Table 660. MEA Rare Disease Drug Sales, by Distribution Channel K Units (2025-2030)
  • Table 661. MEA Rare Disease Drug Sales, by Indication K Units (2025-2030)
  • Table 662. Middle East Rare Disease Drug Sales, by Application K Units (2025-2030)
  • Table 663. Middle East Rare Disease Drug Sales, by Disease K Units (2025-2030)
  • Table 664. Middle East Rare Disease Drug Sales, by Form K Units (2025-2030)
  • Table 665. Middle East Rare Disease Drug Sales, by Distribution Channel K Units (2025-2030)
  • Table 666. Middle East Rare Disease Drug Sales, by Indication K Units (2025-2030)
  • Table 667. Africa Rare Disease Drug Sales, by Application K Units (2025-2030)
  • Table 668. Africa Rare Disease Drug Sales, by Disease K Units (2025-2030)
  • Table 669. Africa Rare Disease Drug Sales, by Form K Units (2025-2030)
  • Table 670. Africa Rare Disease Drug Sales, by Distribution Channel K Units (2025-2030)
  • Table 671. Africa Rare Disease Drug Sales, by Indication K Units (2025-2030)
  • Table 672. North America Rare Disease Drug Sales, by Country K Units (2025-2030)
  • Table 673. North America Rare Disease Drug Sales, by Application K Units (2025-2030)
  • Table 674. North America Rare Disease Drug Sales, by Disease K Units (2025-2030)
  • Table 675. North America Rare Disease Drug Sales, by Form K Units (2025-2030)
  • Table 676. North America Rare Disease Drug Sales, by Distribution Channel K Units (2025-2030)
  • Table 677. North America Rare Disease Drug Sales, by Indication K Units (2025-2030)
  • Table 678. United States Rare Disease Drug Sales, by Application K Units (2025-2030)
  • Table 679. United States Rare Disease Drug Sales, by Disease K Units (2025-2030)
  • Table 680. United States Rare Disease Drug Sales, by Form K Units (2025-2030)
  • Table 681. United States Rare Disease Drug Sales, by Distribution Channel K Units (2025-2030)
  • Table 682. United States Rare Disease Drug Sales, by Indication K Units (2025-2030)
  • Table 683. Canada Rare Disease Drug Sales, by Application K Units (2025-2030)
  • Table 684. Canada Rare Disease Drug Sales, by Disease K Units (2025-2030)
  • Table 685. Canada Rare Disease Drug Sales, by Form K Units (2025-2030)
  • Table 686. Canada Rare Disease Drug Sales, by Distribution Channel K Units (2025-2030)
  • Table 687. Canada Rare Disease Drug Sales, by Indication K Units (2025-2030)
  • Table 688. Mexico Rare Disease Drug Sales, by Application K Units (2025-2030)
  • Table 689. Mexico Rare Disease Drug Sales, by Disease K Units (2025-2030)
  • Table 690. Mexico Rare Disease Drug Sales, by Form K Units (2025-2030)
  • Table 691. Mexico Rare Disease Drug Sales, by Distribution Channel K Units (2025-2030)
  • Table 692. Mexico Rare Disease Drug Sales, by Indication K Units (2025-2030)
  • Table 693. Research Programs/Design for This Report
  • Table 694. Key Data Information from Secondary Sources
  • Table 695. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Rare Disease Drug: by Application USD Million (2018-2023)
  • Figure 5. Global Rare Disease Drug: by Disease USD Million (2018-2023)
  • Figure 6. Global Rare Disease Drug: by Form USD Million (2018-2023)
  • Figure 7. Global Rare Disease Drug: by Distribution Channel USD Million (2018-2023)
  • Figure 8. Global Rare Disease Drug: by Indication USD Million (2018-2023)
  • Figure 9. South America Rare Disease Drug Share (%), by Country
  • Figure 10. Asia Pacific Rare Disease Drug Share (%), by Country
  • Figure 11. Europe Rare Disease Drug Share (%), by Country
  • Figure 12. MEA Rare Disease Drug Share (%), by Country
  • Figure 13. North America Rare Disease Drug Share (%), by Country
  • Figure 14. Global Rare Disease Drug: by Application K Units (2018-2023)
  • Figure 15. Global Rare Disease Drug: by Disease K Units (2018-2023)
  • Figure 16. Global Rare Disease Drug: by Form K Units (2018-2023)
  • Figure 17. Global Rare Disease Drug: by Distribution Channel K Units (2018-2023)
  • Figure 18. Global Rare Disease Drug: by Indication K Units (2018-2023)
  • Figure 19. South America Rare Disease Drug Share (%), by Country
  • Figure 20. Asia Pacific Rare Disease Drug Share (%), by Country
  • Figure 21. Europe Rare Disease Drug Share (%), by Country
  • Figure 22. MEA Rare Disease Drug Share (%), by Country
  • Figure 23. North America Rare Disease Drug Share (%), by Country
  • Figure 24. Global Rare Disease Drug share by Players 2023 (%)
  • Figure 25. Global Rare Disease Drug share by Players (Top 3) 2023(%)
  • Figure 26. Global Rare Disease Drug share by Players (Top 5) 2023(%)
  • Figure 27. BCG Matrix for key Companies
  • Figure 28. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 29. Novartis (Switzerland) Revenue: by Geography 2023
  • Figure 30. Bristol-Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 31. Bristol-Myers Squibb Company (United States) Revenue: by Geography 2023
  • Figure 32. Celgene Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 33. Celgene Corporation (United States) Revenue: by Geography 2023
  • Figure 34. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 35. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2023
  • Figure 36. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 37. Pfizer, Inc. (United States) Revenue: by Geography 2023
  • Figure 38. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 39. Sanofi S.A. (France) Revenue: by Geography 2023
  • Figure 40. Alexion Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 41. Alexion Pharmaceuticals, Inc. (United States) Revenue: by Geography 2023
  • Figure 42. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 43. Eli Lilly and Company (United States) Revenue: by Geography 2023
  • Figure 44. Novo Nordisk A/S (Denmark) Revenue, Net Income and Gross profit
  • Figure 45. Novo Nordisk A/S (Denmark) Revenue: by Geography 2023
  • Figure 46. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 47. AstraZeneca (United Kingdom) Revenue: by Geography 2023
  • Figure 48. Eisai Co., Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 49. Eisai Co., Ltd. (Japan) Revenue: by Geography 2023
  • Figure 50. Daiichi Sankyo Company Limited (Japan) Revenue, Net Income and Gross profit
  • Figure 51. Daiichi Sankyo Company Limited (Japan) Revenue: by Geography 2023
  • Figure 52. Global Rare Disease Drug: by Application USD Million (2025-2030)
  • Figure 53. Global Rare Disease Drug: by Disease USD Million (2025-2030)
  • Figure 54. Global Rare Disease Drug: by Form USD Million (2025-2030)
  • Figure 55. Global Rare Disease Drug: by Distribution Channel USD Million (2025-2030)
  • Figure 56. Global Rare Disease Drug: by Indication USD Million (2025-2030)
  • Figure 57. South America Rare Disease Drug Share (%), by Country
  • Figure 58. Asia Pacific Rare Disease Drug Share (%), by Country
  • Figure 59. Europe Rare Disease Drug Share (%), by Country
  • Figure 60. MEA Rare Disease Drug Share (%), by Country
  • Figure 61. North America Rare Disease Drug Share (%), by Country
  • Figure 62. Global Rare Disease Drug: by Application K Units (2025-2030)
  • Figure 63. Global Rare Disease Drug: by Disease K Units (2025-2030)
  • Figure 64. Global Rare Disease Drug: by Form K Units (2025-2030)
  • Figure 65. Global Rare Disease Drug: by Distribution Channel K Units (2025-2030)
  • Figure 66. Global Rare Disease Drug: by Indication K Units (2025-2030)
  • Figure 67. South America Rare Disease Drug Share (%), by Country
  • Figure 68. Asia Pacific Rare Disease Drug Share (%), by Country
  • Figure 69. Europe Rare Disease Drug Share (%), by Country
  • Figure 70. MEA Rare Disease Drug Share (%), by Country
  • Figure 71. North America Rare Disease Drug Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Novartis (Switzerland)
  • Bristol-Myers Squibb Company (United States)
  • Celgene Corporation (United States)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Pfizer, Inc. (United States)
  • Sanofi S.A. (France)
  • Alexion Pharmaceuticals, Inc. (United States)
  • Eli Lilly and Company (United States)
  • Novo Nordisk A/S (Denmark)
  • AstraZeneca (United Kingdom)
  • Eisai Co., Ltd. (Japan)
  • Daiichi Sankyo Company Limited (Japan)
Additional players considered in the study are as follows:
Bayer AG (Germany) , GlaxoSmithKline (United Kingdom) , Merck & Co., Inc. (United States) , Johnson & Johnson (United States) , Biogen, Inc. (United States)
Select User Access Type

Key Highlights of Report


Apr 2024 244 Pages 72 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Rare Disease Drug Quantitative research analysis
Global Rare Disease Drug Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The key segments that are playing vital role in Rare Disease Drug Market are by end use application [Hospitals, Clinics and Others].
The Rare Disease Drug Market is gaining popularity and expected to see strong valuation by 2030.
  • Rising Awareness among Consumers
  • Technology Advancement in Manufacturing Process
  • Increasing Number of Rare Diseases in North America Regions, it almost occurs in one in ten American

Know More About Global Rare Disease Drug Report?

Have a Query? Click Here

Other Related Reports

Prosthetic Foot Comprehensive Study by Type (Mechanical Foot, Microprocessor Foot), Application (Juveniles, Adults), Prosthetic Products (Lower Extremity Prosthetics, Liners, Sockets, Modular Compone...
$ 3500
Dynamic Compressive Plate Comprehensive Study by Type (Adult Compressive Plate, Children Compressive Plate), Application (Leg, Skull, Forearm, Arm), End users (Hospitals, Clinics), Materials (Titaniu...
$ 3500
Wound Cleanser Products Comprehensive Study by Application (Traumatic Ulcers, Diabetic Ulcers, Pressure Ulcers), End User (Hospital Inpatient Settings, Hospital Outpatient Settings, Ambulatory Surgi...
$ 3450
Disposable Surgical Gowns Comprehensive Study by Type (PP Non-woven material, SMS Non-woven material, Others), Application (Hospitals, Clinics, Others), Distribution Channel (Online Sales, Retail Pha...
$ 3450
Healthcare Furniture Comprehensive Study by Type (Seating, Tables, Casegoods, Outdoor, Other), Application (Lounge / Waiting, Patient Room, Treatment Room, Cafe / Dining, Others), Distribution Channe...
$ 3750
Elastic Bandages Comprehensive Study by Type (Lightweight conforming, Light support, Light compression, Moderate compression, High compression, Extra high compression), Application (Upper Limbs, Lowe...
$ 3450